
Opinion|Videos|July 16, 2024
Navigating Biosimilar Uptake in New Patients
The panel discuss if including biosimilars on formulary at parity is enough to support their adoption.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you direct new-start patients to a biosimilar? What about switching?
- Payers require generic medications over brand name in most instances. Why isn’t this the case for biosimilars?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
2
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
3
'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum
4
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
5












































